Media stories about Cytori Therapeutics (NASDAQ:CYTX) have been trending somewhat positive on Sunday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cytori Therapeutics earned a coverage optimism score of 0.14 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 44.8462083562767 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

A number of equities analysts have weighed in on CYTX shares. Maxim Group set a $5.00 price target on shares of Cytori Therapeutics and gave the stock a “buy” rating in a research note on Monday, November 13th. B. Riley reaffirmed a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th. Finally, Zacks Investment Research downgraded shares of Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th.

Cytori Therapeutics (CYTX) opened at $0.30 on Friday. Cytori Therapeutics has a one year low of $0.22 and a one year high of $2.13. The company has a market cap of $10.59, a price-to-earnings ratio of -0.33 and a beta of 2.75.

Cytori Therapeutics (NASDAQ:CYTX) last issued its earnings results on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.02. Cytori Therapeutics had a negative net margin of 367.33% and a negative return on equity of 228.21%. The business had revenue of $1.77 million for the quarter, compared to the consensus estimate of $2.04 million. During the same quarter last year, the firm posted ($0.26) EPS. analysts anticipate that Cytori Therapeutics will post -0.62 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Cytori Therapeutics (CYTX) Receives News Impact Score of 0.14” was originally reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.dailypolitical.com/2017/12/31/cytori-therapeutics-cytx-receives-news-impact-score-of-0-14.html.

About Cytori Therapeutics

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Insider Buying and Selling by Quarter for Cytori Therapeutics (NASDAQ:CYTX)

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.